contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


guard-therapeutics-announces-changes-to-the-companys-management-team

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Guard Therapeutics bedriver utveckling av läkemedel inom området oxidativ stress. Bolaget fokuserar i första hand på forskning, utveckling och kommersialisering av läkemedel som avser att förhindra uppkomst och komplikationer av akuta njurskador. Läkemedlet har i prekliniska studier visat sig skydda exponerad vävnad och understödja regenerativa processer. Bolaget har sitt huvudkontor i Lund.

Guard Therapeutics

Guard Therapeutics (publ) today announces changes to the company’s management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic...

<div class="mfn-preamble"><p><strong>Guard Therapeutics (publ) today announces changes to the company’s management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review focused on a merger or a reverse takeover (RTO).</strong></p></div><div class="mfn-body"><p>Sara Thuresson, Head of Clinical Operations, is leaving her position and will remain available until 30 April 2026 at the latest.</p><p>Torbjörn Larsson, Head of CMC, is retiring and will be available in his position until 30 April 2026 at the latest.</p><p>The company’s Chief Medical Officer, Michael Reusch, and Head of Preclinical Development, Peter Gilmour, remain contracted on a consultancy basis and will continue to support the company as needed during a transition period to conclude ongoing activities, primarily related to the completed Phase 2b POINTER study.</p><p>“Sara, Torbjörn, Michael and Peter have all made significant and highly appreciated contributions to Guard Therapeutics. Their professionalism, dedication and consistently high quality work have been invaluable to the company’s progress. We are deeply grateful for their contributions and wish them all the very best in their next steps,” says Tobias Agervald, CEO of Guard Therapeutics.</p></div><div class="mfn-footer mfn-contacts mfn-5da762a72d6c"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p><strong>Tobias Agervald,&nbsp;CEO</strong><br>Telephone:&nbsp;+46 8&nbsp;670 65 51<br>E-mail: info@guardtherapeutics.com&nbsp;</p></div><div class="mfn-footer mfn-about mfn-33a07df364dd"><p><strong class="mfn-heading-1">About Guard Therapeutics</strong></p><hr><p>Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company’s candidate drugs are based on the endogenous protein alpha-1-microglobulin (A1M). Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).</p><p>Certified Adviser is Redeye AB, <a rel="noopener" href="https://www.redeye.se/advisory/certified-adviser">Certified Adviser - Redeye</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/11fc7b65-4a12-472a-afff-c66ace66fc90/guard-therapeutics-announces-changes-to-the-companys-management-team.pdf" class="mfn-generated mfn-primary">Guard Therapeutics Announces Changes to the Company’s Management Team</a></p></div>